AbbVie and REGENXBIO Announce Eye Care Collaboration
AbbVie and REGENXBIO form a strategic partnership combining eye care and gene therapy expertise
Companies will develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other ch... Biopharmaceuticals, Regenerative Medicine, Ophthalmology AbbVie, REGENXBIO, gene therapy, macular degeneration, diabetic retinopathy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Age-Related Macular Degeneration (AMD) | Diabetes | Endocrinology | Gene Therapy | Genetics | Opthalmology | Partnerships | Pharmaceuticals